Zymeworks is a Vancouver biopharmaceutical company focused on novel antibody-based medicines for difficult-to-treat diseases. Its website describes a royalty-driven business supported by in-house R&D, proprietary antibody technology platforms, and global partnerships. The company is active in antibody therapeutics and related platform science, with both partnered assets and internal pipeline capabilities.